Data Factory
Reading the graph
Reading the graph
Venture Capital
Naarden
Shaping new life-science ventures.
Data as of (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built and rebuilt at most every 15 minutes.
This entity has not been resolved onto another DFX graph by a shared identifier. A name match elsewhere would be a candidate, never an identity, and none is recorded.
| Fund | Vintage | Lifecycle | Form D sold | GAV | LPs |
|---|---|---|---|---|---|
| Biogeneration Capital Fund IV C.V. | n/a | Unknown | n/a | $58.1M | 0 |
| Fonds Investeringsrijpe Starters (first) Cooperatief U.A. | n/a | Unknown | n/a | $3.7M | 0 |
| Biogeneration Capital Fund V | n/a | Unknown | n/a | $3.3M | 0 |
| Biogeneration Capital Fund III C.V. | n/a | Unknown | n/a | $83.2M | 0 |
| Biogeneration III Co-Investment Fund C.V. | n/a | Unknown | n/a | $6.6M | 0 |
| Company | State | Stage | Round size | Partner | Attribution | Observed |
|---|---|---|---|---|---|---|
| Avidicure | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Azafaros | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Brandaris Therapeutics | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Brenig | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| CatalYm | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Citryll | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Complement Therapeutics | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Confo Therapeutics | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Dunad | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Epsilogen Pioneering Radically New Antibody Therapeutics in Oncology | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Fibrocor | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| FundaMental Pharma | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Genase Therapeutics | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Kivu Bioscience | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Mironid | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| NorthSea Therapeutics | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Phlox | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Phosphoenix | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| River BioMedics | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| RougeTx | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Scenic Biotech | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Stant | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Tanai Therapeutics | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| TargED Biopharmaceuticals | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Tessellate Bio | n/a | n/a | n/a | n/a | Unknown | Sep 16, 2026 |
| Investor | Co-investor | Shared deals | Shared companies | Last observed | Strength |
|---|---|---|---|---|---|
| Biogeneration III Services B.V. | Canaan Partners | 1 | 1 | Sep 16, 2026 | One time |
| Biogeneration III Services B.V. | HealthCap | 1 | 1 | Sep 16, 2026 | One time |
| Biogeneration III Services B.V. | Avoro Capital Advisors LLC | 1 | 1 | Sep 16, 2026 | One time |
| NSV Management LLC | Biogeneration III Services B.V. | 1 | 1 | Sep 16, 2026 | One time |
| Omega Fund Management, LLC | Biogeneration III Services B.V. | 1 | 1 | Sep 16, 2026 | One time |
Also named here, with no published line of their own (reach them through the firm): Edward van Wezel (Managing Partner), Oskar Slotboom (Managing Partner), Daniela Couto (General Partner), Roger Ulrich (Senior Advisor), Andree Blaukat (Senior Advisor), Robbert van de Griendt (Head of Investment Relations), Cyril Lesser (Vice President Finance | Funds), Laura Asbjornsen (Head of Communications), Machteld Groeneveld (Chief Compliance Officer & Legal Affairs), Patricia Vonk (AML/KYC Manager), Claire van Viersen (Executive Assistant), Case Studies (Portfolio).
Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan